Exhibit 12.1
OncoGenex Pharmaceuticals, Inc.
Statement of Computation of Ratio of Earnings to Fixed Charges
Fiscal Year Ended December 31, | Six Months Ended June 30, 2015 | |||||||||||||||||||||||
(In $000’s, except ratio) | 2010 | 2011 | 2012 | 2013 | 2014 | |||||||||||||||||||
Fixed Charges: | ||||||||||||||||||||||||
Interest expense | $ | 1,172 | $ | 1,086 | $ | 976 | $ | 848 | $ | 699 | $ | 156 | ||||||||||||
Amortized premiums, discounts and capitalized expenses related to indebtedness | — | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
| $ | 1,172 | $ | 1,086 | $ | 976 | $ | 848 | $ | 699 | $ | 156 | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Earnings (loss): | ||||||||||||||||||||||||
Net loss before income tax benefit (provision) | $ | (15,584 | ) | $ | (14,673 | ) | $ | (21,098 | ) | $ | (31,849 | ) | $ | (26,240 | ) | $ | (10,527 | ) | ||||||
Add fixed charges | 1,172 | 1,086 | 976 | 848 | 699 | 156 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
| $ | (14,412 | ) | $ | (13,587 | ) | $ | (20,122 | ) | $ | (31,001 | ) | $ | (25,541 | ) | $ | (10,371 | ) | |||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Ratio of earnings to fixed charges | — | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Deficiency of earnings to fixed charges | $ | (15,584 | ) | $ | (14,673 | ) | $ | (21,098 | ) | $ | (31,849 | ) | $ | (26,240 | ) | $ | (10,527 | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
